Options are eyeing the drug sector's Alzheimer's treatments, according to one observer.
"There haven't been a lot of bright spots in the market this week, but developers of Alzheimer's drugs have gotten particular attention, and that's been a very optimistic story, on news that Elan and Wyeth had experienced promising signs for trials of their drug, but I think that the real way to play this sector is in Myriad Generics, which has a drug under development called Flurizan, which has just finished Phase III trials, and they are due to release data on that drug over the next week or two," Rebecca Darst of Interactive Brokers said on CNBC's "Squawk Box." "There's not a specific date for that release, but we expect that it's going to coincide with the July options contract. Interestingly, there's potentially a $20 million market for Alzheimer's drugs, and, really, the sector is banking on these selective amyloid-lowering agents, which treat the causes rather than the symptoms.